Skip to main content
main-content
Top

11-02-2021 | COVID-19 | Podcast | Article

Repurposing rheumatology drugs for COVID-19: Interleukin inhibitors

Speaker: Cristina Mussini

In this series of podcasts we are speaking to the experts about repurposing rheumatology drugs for the treatment and prevention of COVID-19. 

For this episode, Cristina Mussini, Professor of Infectious Diseases at the University of Modena and Reggio Emilia in Italy, talks about interleukin inhibitors. She summarizes the current data on these agents, discusses why tocilizumab has given rise to clinical benefits in some studies but not others, and outlines what further work needs to be done (19:10).

Listen below or subscribe to this Podcast on:

Google PodcastsApple Podcasts | SpotifyStitcher | TuneIn

About the speaker

Cristina Mussini

Cristina is Professor of Infectious Diseases at the University of Modena and Reggio Emilia, and Director of Clinic of Infectious Diseases at Azienda Ospedaliero-Universitaria Policlinico in Modena, Italy.


Full biography

Related topics

Repurposing rheumatology drugs for COVID-19

Experts discuss the rationale, data on different agents, and the potential impact on rheumatology practice.

  • » Featuring insights from the COVID-19 Global Rheumatology Alliance, EULAR, and the Lupus Foundation of America
Image Credits